KBC Group NV, headquartered in Brussels, Belgium, is a bank-insurance firm that offers integrated financial services primarily to retail clients, private banking, small and medium-sized enterprises, and mid-cap clients. The company provides a wide range of products, including demand deposits, savings accounts, home and mortgage loans, consumer finance, and SME funding. Additionally, KBC offers life and non-life insurance, asset management, cash management, trade finance, leasing, and corporate finance services. The firm operates numerous branches across Belgium, the Czech Republic, Hungary, Bulgaria, and Ireland, serving customers through various channels, including agents and electronic platforms. KBC Private Equity, a subsidiary of KBC Group, focuses on providing development capital and financing buy-outs for medium-sized companies, with a commitment to becoming a leading private equity provider in its home markets. Established in 1935, KBC Group has evolved to meet the diverse financial needs of its clientele while maintaining a strong presence in Central and Eastern Europe.
The revolution in learning, the skills of tomorrow trained today. At Stellar Labs we have found a way to solve the skills gap in the tech sector. A science based way, backed by research to achieve the best performance and return on investment. Learners are energised and engaged to quickly master high-demand technical skills and capabilities. We focus on results-driven solutions to help the technical workforce thrive today and lead the change into tomorrow. The technology market is booming, but the industry faces a global talent shortage. Stellar Labs provides the answer – and the competitive advantage.
Wizata SA, founded in 2014 and based in Capellen, Luxembourg, specializes in developing platform-as-a-service solutions tailored for the manufacturing industry. The company's software focuses on enhancing quality control, maintenance, and overall performance within manufacturing processes. By leveraging artificial intelligence, Wizata provides tools that address critical areas such as production optimization, quality sustainability, and predictive maintenance. The company also caters to various sectors, including insurance, energy, healthcare, and e-commerce, aiming to uncover valuable insights from both internal and external data. Through collaboration with industry experts and data scientists, Wizata offers customized solutions to help clients navigate the complexities of their specific challenges and identify unexploited opportunities.
ArtiQ NV is a Belgian company founded in 2019 as a spin-off from the University of Leuven, specializing in artificial intelligence-driven medical software for respiratory care. The company has developed ArtiQ|PFT, a software solution that automates the processing of pulmonary function test data, facilitating the diagnosis, treatment, and monitoring of lung diseases. By leveraging AI technology, ArtiQ|PFT enhances the accuracy and efficiency of interpreting test results, providing healthcare professionals with insights into disease patterns and probabilities, as well as recommendations for patient management. With a focus on improving the diagnostic environment for lung diseases, ArtiQ aims to serve as a reliable partner for medical practitioners and contribute positively to patient outcomes and the healthcare system.
Fnality International is a London-based company that provides a digital cash system utilizing blockchain technology to facilitate financial transactions. Established in April 2019, Fnality emerged from a four-year research and development initiative known as the "Utility Settlement Coin," initially proposed by UBS in collaboration with Clearmatics. The company's platform aims to transform wholesale financial markets by enabling instant, irrevocable, and low-cost settlements. By leveraging distributed ledger technology, Fnality seeks to eliminate intraday credit risk and reduce counterparty exposure, thus helping financial institutions streamline operations, enhance liquidity, and minimize systemic risk.
Joyn Belgium operates a customer engagement platform that enhances the relationship between merchants and their customers. The platform allows users to utilize a loyalty card that enables them to earn rewards points while shopping at their preferred stores. Customers can redeem these points for various benefits, including discounts and prizes, fostering loyalty and repeat business. By integrating the efforts of numerous local merchants, Joyn provides a unified app that offers unique advantages to customers, encouraging them to return to participating businesses. This approach not only supports merchants in growing their customer base but also helps consumers discover valuable rewards and promotions from a diverse range of local retailers.
Interlease is a Bulgarian leasing company that operates under the umbrella of the Belgian banking and insurance group KBC. It specializes in providing financing and leasing services for a variety of assets, including high-quality equipment, transportation vehicles, and office supplies. By enabling Bulgarian enterprises to acquire necessary resources, Interlease aims to enhance their competitiveness and market positions both locally and internationally. The company also emphasizes customer support after the delivery of assets by utilizing effective internet and mobile technologies, allowing clients to select their preferred suppliers and asset types that best fit their business needs.
United Bulgarian Bank is a prominent financial institution in Bulgaria, offering a wide range of banking products and services tailored for individual, microbusiness, and corporate clients. The bank provides various deposit options, including savings accounts, current accounts, and online deposits, alongside an array of loan products such as consumer loans, mortgage loans, and working capital loans. Additionally, United Bulgarian Bank issues debit and credit cards and offers services in insurance, investment banking, mobile banking, and trade finance. With a focus on personalized banking, the bank strives to meet the diverse financial needs of its retail and commercial clients, primarily based in Sofia.
CitizenLab NV is a civic engagement software company based in Brussels, Belgium, founded in 2015. The company offers a platform designed for city governments to enhance citizen participation in decision-making processes. Its features enable two-way communication between local authorities and residents, allowing citizens to propose and discuss ideas, vote on them, and provide feedback through polls and surveys. The platform also includes tools for city managers to visualize decision-making through timelines and maps, as well as analytics and reporting features to facilitate informed decision-making. By promoting transparency and collaboration, CitizenLab aims to make governance more democratic and effectively engage citizens in shaping their communities.
VB LEASING SK, spol. s r.o. is a leasing company based in Bratislava, Slovakia, specializing in the financing of movable objects. The company provides financial solutions for personal and utility vehicles, machinery, equipment, technology, and computing systems. It also offers credit financing options to both corporate and private clients. Established in 1994, VB LEASING SK operates through a network of 11 branches and collaborates with 90 dealers and agents, employing around 90 full-time staff. The company was previously known as LB-Leasing spol. s r.o. before rebranding in 2002 and is currently a subsidiary of CSOB Leasing, a.s.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
BIC specialises in assisting international investors in acquiring businesses, as well as local companies in attracting strategic partners, and can look back on a number of successfully completed M&A transactions. From one region to another, the value of the deals it works on varies between 10 and 200 million euros. Its business portfolio is spread evenly across the various regions in which the company operates. BIC targets midcaps and is a strong player in the financial services, consumer goods, retail, distribution and selected industrial sectors.
Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Istrobanka is a provider of retail and wholesale banking products and services for corporate and individual customers in Slovakia. The company offers deposit products, savings and investment accounts, loans, corporate finance, insurance products, payment cards, mutual funds, and mortgage loans.
Richelieu Finance
Acquisition in 2008
Richelieu Finance is an investment management company.
Senzal is a privately held brokerage service company that specializes in providing security brokerage services. The firm focuses on facilitating the buying and selling of securities for its clients, ensuring efficient transactions and access to various financial markets. With a commitment to delivering reliable brokerage solutions, Senzal aims to meet the diverse needs of its clientele in the financial sector.
Ceres, Inc. is an agricultural biotechnology company that develops and markets seeds and traits aimed at producing crops for various markets, including feed and renewable biomass. Headquartered in Thousand Oaks, California, the company utilizes advanced plant breeding, biotechnology, and bioinformatics to create seed products that address agricultural challenges. Ceres offers forage sorghum seeds for livestock feed and biotechnology traits that improve biomass yields and provide resilience to drought and other stressors for crops like sugar cane. It also markets sweet sorghum and high biomass sorghum varieties, which serve as feedstocks for biofuels and bio-based chemicals, thereby supporting energy production. The company’s seed products are marketed under the Blade brand. Ceres, Inc. operates as a subsidiary of Land O'Lakes, Inc., following its establishment in 1996.
Absolut Bank, established in 1993 and based in Moscow, Russia, provides a wide range of commercial banking services to approximately 200,000 clients nationwide. The bank serves over 30,000 corporate clients across various sectors, including consumer goods, metals, machine-building, automotive, oil, energy, and telecommunications. Its offerings encompass a comprehensive suite of financial services such as financing, cash and settlement services, and investment opportunities. Additionally, Absolut Bank places a strong emphasis on developing services for individual clients, striving to provide competitive terms and exceptional service. The bank also facilitates personal banking, online banking, mobile banking, and treasury management services, positioning itself as a versatile financial partner in the Russian market.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Romstal Leasing is the largest independent leasing company in Romania. At the end of 2006, it held a 4.20% share of the Romanian leasing market and was ranked thirteenth. The bulk of its financing activity (43.30%) relates to car leasing, but it also leases delivery vans, lorries, machinery and equipment and real estate.
Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.
Banco Urquijo specializes in advising and managing legal entities, such as insurance companies, mutual companies, provident societies, cooperatives, and trusts that administer third party assets.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
K&H Bank is a banking institution based in Budapest, Hungary, established in 1987. It operates in both retail and corporate segments, offering a wide range of financial services and solutions. These services include corporate finance, agricultural loans, leasing, and funding for local governments. As a wholly owned subsidiary of KBC Bank, K&H Bank focuses on providing its clients with comprehensive financial advice to help them make informed decisions.
HSBC Dewaay SA is a privately held company offers private banking and trustee services. It services include cash management, discretionary portfolio management, and patrimonial advisory services.
Effectenbank Stroeve N.V.
Acquisition in 2005
Effectenbank Stroeve N.V. is a privately held company offers capital management, stockbroking, and investment advisory services.
Aurel Leven
Acquisition in 2005
Aurel Leven Gestion, an independent asset management company, old, which manages funds on behalf of private clients and institutional investors. Aurel Leven Gestion, of February 2005, Aurel Leven Gestion was acquired by KBL France Gestion.
Almanij NV
Acquisition in 2005
Almanij NV engages in banking, insurance, and investment activities; and the provision of specialized financial services.
Aballea Finance SA is a privately held company specializing in wealth management and real estate management. It offers a range of financial advisory services, including real estate consulting, investment management, tax assistance, and financial reporting. The company's focus is on providing tailored solutions to meet the diverse needs of its clients, ensuring effective management of their financial and real estate assets.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
WARTA S.A. was established in 1920. Since then it's been setting standards on the Polish insurance market. The Company is one of the largest and oldest insurance companies in Poland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.